GleamWall
中文EN

DYAI DYADIC INTERNATIONAL INC

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1213809 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-7.6%
TTM net income YoY4.7%
TTM EPS YoY13.0%
Revenue 3-yr CAGR1.5%
Net income 3-yr CAGR—

Margins

Gross margin17.9%
Operating margin-236.7%
Net margin-226.9%
FCF margin—
EBITDA margin—

Returns

ROE-47,256.0%
ROA-71.4%
ROIC (approx.)—
Asset turnover0.31x

Leverage & solvency

Liabilities / assets132.5%
Debt / equity—
Current ratio1.69x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.00x
Accruals ratio0.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$3.09M$3.50M
Cost of revenue$2.32M$1.19M
Gross profit$770,485$2.30M
R&D expense$2.15M$2.04M
SG&A expense$5.76M$6.13M
Operating income-$7.19M-$5.90M
Pretax income-$7.33M-$5.76M
Net income-$7.36M-$5.81M
EPS (basic)-0.23-0.20
EPS (diluted)-0.23-0.20
Weighted avg. shares (diluted)32.62M29.32M
Balance sheet
Cash & equivalents$4.62M$6.51M
Short-term investments$2.70M$2.76M
Receivables$1.09M$237,027
Current assets$9.90M$9.83M
Total assets$9.95M$9.93M
Current liabilities$3.69M$2.45M
Total liabilities$8.71M$7.46M
Shareholders' equity$1.23M$2.47M
Shares outstanding36.19M29.84M
Cash flow statement
Operating cash flow-$5.70M-$3.97M
Investing cash flow$82,085-$1.88M
Financing cash flow$4.96M$5.85M
Stock-based compensation$930,183$1.13M

Free plan shows the latest 2 periods; Pro shows all 9 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.